Grants for State governments - Federal

The Pre-Disaster Mitigation (PDM) Grant Program makes federal funds available to state, local, tribal, and territorial governments to plan for and implement sustainable cost-effective measures designed to reduce the risk to individuals and property from future natural hazards, while also reducing reliance on federal funding from future natural disasters. The Fiscal Year (FY) 2024 PDM Grant Program will provide $190,568,289 in funding to projects identified in the FY24 DHS Appropriations Acts Joint Explanatory Statement (JES) for Division C in the table starting on page 59 entitled Homeland Security Community Project Funding/Congressionally Directed Spending.The PDM Grant Program aligns with the general goal of promoting resilience and adaptation in light of current risks and the 2020-2024 DHS Strategic Plan through pursuing Goal 5: Strengthen Preparedness and Resilience. Specifically, Objective 5.1: Build a National Culture of Preparedness has several sub-objectives that the PDM Grant Program supports. PDM serves primarily to bolster Sub-Objective 5.1.1: Incentivize investments that reduce risk and increase pre-disaster mitigation, including expanding the use of insurance to manage risk through funding mitigation projects, particularly ones that reduce risk to Community Lifelines and infrastructure. Additionally, project scoping activities that PDM funds also contribute to other sub-objectives. For example, planning, partnerships, and project scoping efforts help improve awareness initiatives to encourage public action to increase preparedness (Sub-Objective 5.1.2), use lessons from past disasters and exercises to inform community investment decisions and anticipate challenges that may emerge during future disasters (Sub-Objective 5.1.3), and coordinate and guide continuity of operations activities through partnerships with government and non-government stakeholders (Sub-Objective 5.1.5).The 2022-2026 FEMA Strategic Plan outlines three bold, ambitious goals in order to position FEMA to address the increasing range and complexity of disasters, support the diversity of communities we serve, and complement the nations growing expectations of the emergency management community. The PDM Grant Program supports Goal 2: Lead Whole of Community in Climate Resilience and Goal 3: Promote and Sustain a Ready FEMA and a Prepared Nation.

This funding opportunity supports organizations in planning and hosting an annual conference focused on advancing the development of treatments for substance use disorders, bringing together researchers, clinicians, and policymakers to foster collaboration and innovation in this critical public health area.

This funding opportunity supports research projects that aim to reduce health disparities related to HIV and substance use among underserved racial and ethnic populations in the U.S.

Amendment 000001 - Extending the Full Application Submission Deadline to July 18, 2024, updating Expected Date for DOE Selection Notifications, and updating the Expected Timeframe for Award Negotiations. Additionally, the expected number of awards in Topic Area 1 has been updated. Building a clean and equitable energy economy and addressing the climate crisis is a top priority of the Biden Administration. This FOA will advance the Biden Administrations goals to deliver an equitable, clean energy future, and put the United States on a path to achieve net-zero emissions, economy-wide, by no later than 2050 to the benefit of all Americans. This FOA is funded by two Department of Energy (DOE) offices: the Office of Energy Efficiency and Renewable Energys (EERE) Bioenergy Technologies Office (BETO) and the Office of Fossil Energy and Carbon Managements (FECM) Carbon Conversion Program. BETOs primary focus is on developing technologies that convert domestic biomass and/or waste resources to affordable biofuels and bioproducts that significantly reduce carbon emissions on a life-cycle basis as compared to equivalent petroleum-based products. These bioenergy technologies can enable a transition to a clean energy economy, create high-quality jobs, support rural economies, and spur innovation in renewable energy and chemicals production. The activities funded by BETO through this funding opportunity will mobilize public clean energy investment by addressing research and development (R) challenges in the conversion of various seaweeds and blends of seaweeds (with wet waste feedstocks such as waste microalgae) to low-carbon fuels and chemicals. These activities can also help develop solutions for communities that are affected by harmful algal blooms to reduce the costs associated with managing these wastes. The priority of FECMs Carbon Conversion Program is to develop multiple pathways by which captured and concentrated carbon dioxide (CO2) is converted into economically viable and environmentally sustainable products. The near-term objective of this programs R is to accelerate deployment of carbon management technologies through the conversion of CO2 into value-added products. Under this FOA, applications are sought that use anthropogenic carbon dioxide emissions in the cultivation process and then convert macro and/or micro algae into low carbon products. Conversion for agricultural products such as animal feed are of particular interest. Algae is a promising type of renewable biomass-based feedstock with the potential to contribute to BETOs and FECMs missions and help meet the aggressive clean energy goals being pursued by DOE. For purposes of this FOA, algae includes microalgae, cyanobacteria, and macroalgae (also referred to as seaweed). All types of algae may be of interest to this FOA, subject to the topic-specific requirements described in each Topic Area. Topic Area 1: Conversion of Seaweeds to Low-Carbon Fuels and Bioproducts Topic Area 2: Conversion of Algal Biomass for Low-Carbon Agricultural Bioproducts Questions regarding the FOA must be submitted to [email protected]. The eXCHANGE system is currently designed to enforce hard deadlines for Concept Paper and Full Application submissions. The APPLY and SUBMIT buttons automatically disable at the defined submission deadlines. The intention of this design is to consistently enforce a standard deadline for all applicants. Applicants that experience issues with submissions PRIOR to the FOA Deadline: In the event that an Applicant experiences technical difficulties with a submission, the Applicant should contact the eXCHANGE helpdesk for assistance ([email protected]). The eXCHANGE helpdesk and/or the EERE eXCHANGE System Administrators ([email protected]) will assist the Applicant in resolving all issues. Applicants that experience issues with submissions that result in a late submission: In the event that an Applicant experiences technical difficulties with a submission that results in a late submission, the Applicant should contact the eXCHANGE helpdesk for assistance ([email protected]). The eXCHANGE helpdesk and/or the EERE eXCHANGE System Administrators ([email protected]) will assist the Applicant in resolving all issues (including finalizing the submission on behalf of, and with the Applicant's concurrence). DOE will only accept late applications when the Applicant has a) encountered technical difficulties beyond their control; b) has contacted the eXCHANGE helpdesk for assistance; and c) has submitted the application through eXCHANGE within 24 hours of the FOA's posted deadline. Please view the full FOA by visiting EERE-Exchange.energy.gov. The required Concept Paper due date for this FOA is 05/10/2024 at 5PM ET. The Full Application due date for this FOA is 6/27/2024 at 5PM ET.

The purpose of this concept is to facilitate the formation and maintenance of multidisciplinary research teams ready to employ epidemiological and/or etiological datasets and analyses to answer substance use prevention research questions and apply findings to intervention development or implementation. Projects supported through this concept will combine hands-on meeting formats, including both sandpit and hackathon approaches, with activities to sustain new research teams and networks, creating a foundational structure for research programs that have impact across disciplines.

This funding opportunity provides financial support to a range of organizations working in Kenya to strengthen health systems for effective management and control of HIV and TB, while promoting sustainable healthcare practices and improving public health responses.

OJP is committed to advancing work that promotes civil rights and equity, increases access to justice, supports crime victims and individuals impacted by the justice system, strengthens community safety, protects the public from crime and evolving threats, and builds trust between law enforcement and the community.With this solicitation, OVC seeks applications for funding under the FY 2024 VOCA Victim Assistance Formula Grant Program. This program furthers the Departments mission by providing grants to support the provision of services to victims of crime throughout the nation. OVC encourages SAAs to use VOCA funding within program parameters to affirmatively advance equity, civil rights, justice, and equal opportunity. In line with these goals, OVC particularly encourages SAAs to include American Indian and Alaska Native tribes in program planning and funding.This program furthers the DOJs mission to uphold the rule of law, to keep our country safe, and to protect civil rights.

This funding opportunity supports interdisciplinary research centers focused on advancing the understanding and treatment of communication disorders, such as hearing and speech issues, through collaborative projects and clinical trials.

This funding opportunity supports advanced pre-clinical research projects that utilize nanotechnology to improve cancer treatment and diagnostics, aiming to transition these innovations toward clinical applications.

This funding opportunity supports early-career researchers in the U.S. to develop their skills in implementation science for effective substance use prevention and treatment, enabling them to lead clinical trials that address the opioid crisis.

This funding opportunity supports projects that preserve Kenya's cultural heritage, including historic sites, museum collections, and traditional practices, targeting eligible educational institutions, NGOs, and organizations dedicated to cultural preservation.

This funding opportunity provides significant financial support to U.S. higher education institutions and research organizations with established HIV/AIDS research programs, enabling them to enhance their research infrastructure and foster interdisciplinary collaboration in the fight against HIV/AIDS.

This grant provides funding to various organizations and governments for projects that protect and restore habitats for neotropical migratory birds across the Americas, with a strong emphasis on international collaboration and partner contributions.

The Office of Minority Health announces the anticipated availability of funds for Fiscal Year (FY) 2025 under the authority of 42 U.S.C. 300u-6 (Section 1707 of the Public Health Service Act) for a demonstration project that supports the development of a National Coordinating Center for Language Access Services . Demonstration projects are time-limited projects for the purpose of assessing the effectiveness of an approach or intervention toward reaching a desired outcome. We expect award recipients under this opportunity to consider approaches to sustainability beyond the end of the support provided by OMH.Individuals with limited English proficiency face barriers to health care and social services that increase their risk for poor health outcomes. We intend for the funded project to create a National Coordinating Center to connect health and human service professionals with qualified health language interpreters and translators to improve access to language services for individuals limited English proficiency. The funded project will develop technical components needed to host the Center, connect and engage a collaborative network of community-based organizations, and promote the Center nationally to health and human service organizations and agencies. OMH also expects the project to address gaps in access to language services and improve the quality of care and health outcomes for individuals with limited English proficiency. Eligible applicants include any private nonprofit or public entity located in a State. State includes, in addition to the several States, only the District of Columbia, Guam, the Commonwealth of Puerto Rico, the Northern Mariana Islands, the Virgin Islands, American Samoa, the Trust Territory of the Pacific Islands, and any agency or instrumentality thereof exclusive of local governments. (42 U.S.C. 201(f) (PHS Act, Section 2(f)), 45 C.F.R. 75.2). Eligible entities include private nonprofit or public faith-based organizations, community-based organizations, and American Indian/Alaska Native/Native American (AI/AN/NA) organizations. Applications must be submitted through Grants.gov, and applicants must have an active SAM.gov registration when submitting an application. Interested applicants are strongly encouraged begin the registration process for both systems early.

This funding opportunity provides financial support to organizations working to enhance a digital system that streamlines the placement of children across state lines for foster care and adoption, ensuring all U.S. jurisdictions are integrated by the 2027 deadline.

This funding opportunity provides financial support to research institutions for developing and sharing essential resources to advance the study of Polycystic Kidney Disease, fostering collaboration and innovation in the field.

This funding opportunity provides financial support to states, local governments, and Tribal entities to reduce flood risks and enhance resilience in communities affected by flooding, particularly those participating in the National Flood Insurance Program.

This modification (000001) includes: -FOA includes the addition of Section IV.A.ii (Applicant Education Services) This FOA solicits proposals for RD associated with Scalable Concentrating Solar Collectors, Scalable Supercritical Carbon Dioxide (sCO2) and Scalable Concentrating Solar-thermal Receivers and Reactors. The three technologies will support the government-wide approach to the climate crisis by driving the innovation that can lead to the deployment of clean energy technologies, which are critical for climate protection.

The FY24 PCRP Physician Research Award supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. The mentored physician is considered the Principal Investigator (PI) of the application. This award emphasizes equally the quality of the proposed research project and the career development of the PI, which should prepare physicians for careers in basic, population science, translational, or clinical prostate cancer research. All applications for the FY24 PCRP Physician Research Award are to be written by the PI, with appropriate direction from the mentor(s).Key elements of this award mechanism are as follows: Principal Investigator: Physicians with clinical duties and/or responsibilities who, at the application submission deadline, are either in the last year of an accredited graduate medical education program as a resident or fellow or within 5 years of having initiated a faculty appointment (including Instructor positions) are eligible to apply. The PI must demonstrate a commitment to a career as a physician-scientist and investigator at the forefront of prostate cancer research and clinical practice; however, the PI is not required to have previous prostate cancer research experience. The award is intended to provide protection of the PIs time for prostate cancer research. Applications are strongly encouraged to demonstrate protection of at least 20% of the PIs time for prostate cancer research, which is not required to be exclusive to this award but can include effort dedicated to other prostate cancer research projects. Mentor(s): This award requires the involvement of at least one designated mentor with an established research program in prostate cancer, as evidenced by recent publications, active funding, and successful mentorship. In addition, the mentor(s) must demonstrate a commitment to advancing the PIs career in prostate cancer research. Research Approach: Proposed research ideas are required to address one or more of the FY24 PCRP Overarching Challenges. The scientific rationale and experimental methodology should demonstrate in-depth analysis of the research problem presented. The feasibility of the research design and methods should be well defined, and a clear plan should be articulated as to how the proposed goals of the project can be achieved. The inclusion of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required. Any preliminary data provided should be from the PI, mentor(s), or member(s) of the collaborating team. Additionally, required resources should be identified and supported through documentation. Research involving human subjects is permitted under this funding opportunity but is restricted to studies without clinical trials. Correlative studies associated with an existing clinical trial are particularly encouraged, provided they are determined to be no greater than minimal risk by the Institutional Review Board (IRB) of record and the USAMRDC Office of Human and Animal Research Oversight (OHARO), Office of Human Research Oversight. Researcher Development Plan: An individualized researcher development plan is required and should be prepared with appropriate guidance from the mentor(s). The researcher development plan should include a clearly articulated strategy for acquiring the necessary skills, competence, and expertise that will enable the PI to successfully complete the proposed research project and foster the PIs development as an independent prostate cancer physician-scientist. An environment appropriate to the proposed mentoring and research project must be clearly described, although any deficiencies of resources and/or mentorship at the PIs institution can be mitigated through collaboration(s) with other institutions. If the PI will be utilizing resources at another institution to successfully complete the proposed project, then the PI is strongly encouraged to designate a co-mentor at the collaborating institution. Impact: The proposed research must address and provide a solution to one or more of the FY24 PCRP Overarching Challenges and ultimately should have the potential to make a significant impact on the programs mission of eliminating death and suffering from prostate cancer and enhancing the well-being of Service Members and their Families, Veterans, and all the patients and caregivers who are experiencing the impact of the disease.Investigators are strongly encouraged to incorporate the following components into their study design, where appropriate, in order to maximize the potential impact of the proposed research project: authentication of proposed cell lines; statistical rigor of preclinical animal experiments; and incorporation of experiments to assess clinical relevance and translatability of findings. Studies utilizing data that are derived from large patient studies that include long-term health records, biospecimen repositories, and pre-existing research and apply state-of-the-art genomic and/or proteomic analysis, bioinformatics, and/or mathematical models to such data are also encouraged. Investigators are highly encouraged to provide a letter of support indicating access to and the availability of any resources required to support the study.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/ journal/v490/n7419/full/nature11556.html. While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP PRA Award should not exceed $750,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $4.80M to fund approximately four PCRP Physician Research Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity supports research and evaluation projects that address the needs of special populations in corrections, improve workforce management, and enhance correctional culture and safety, inviting a wide range of organizations to collaborate on innovative solutions.